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Abstract
Purpose
Several studies reported the increased risk of second primary pancreatic ductal adenocarci-
noma (2nd PDAC) in cancer survivors. However, data on the characteristics of 2nd PDAC
are insufficient.
Methods
This retrospective cohort study included 1759 patients with PDAC. They were classified as
having 2nd PDAC or first primary PDAC (1st PDAC) according to a prior diagnosed cancer
of different origin, at least 6 months before PDAC diagnosis.
Results
There were 110 patients (6.4%) with 2nd PDAC and 1606 (93.6%) patients with 1st PDAC.
Patients with 2nd PDAC presented with older age (66.5 vs. 62.2 years, p < 0.001) and higher
rate of resectability (26.4% vs. 15.9%, p = 0.004) at diagnosis than those with 1st PDAC.
Multivariate analysis without considering resectable status showed that 2nd PDAC (hazard
ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94, p = 0.016) was associated with bet-
ter overall survival. After adjusting for resectable status, however, 2nd PDAC (HR 0.85,
95% CI 0.66–1.09, p = 0.198) was no longer associated with overall survival. When sub-
groups were separately analyzed according to initial treatment modality, the effectiveness of
surgery and chemotherapy were similar between 2nd and 1st PDAC (33.1 vs. 28.5 months,
p = 0.860 and 10.8 vs. 10.7 months, p = 0.952).
Conclusions
The proportion of resectable cases was significantly higher in 2nd PDAC. When surgery
with curative aim was possible, the overall survival was increased even in patients with 2nd
PDAC. These results suggest the importance of screening for second primary cancer in can-
cer survivors.
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Introduction
Second primary cancer is a new neoplasm that is biologically independent of a prior cancer.[1]
The second primary cancer may share genetic factors or environmental background with the
prior cancer, such as alcohol consumption, smoking, genetic syndromes/predisposition, and
underlying diseases, which may be precancerous factors. Moreover, exposure to chemotherapy
and radiation for prior cancer and receiving surgery can be predisposing factors to a second
primary cancer. There were previous reports about an increased risk of secondary malignan-
cies in cancer survivors.[2–4] The development of diagnostic and therapeutic techniques for
malignancy has increased both the life span and the risk of second malignancies in cancer sur-
vivors. In the United States, the proportion of cancer survivors among the total population is
estimated to be 3.5%, and about 10% of newly diagnosed cancers develop in cancer survivors.
[5, 6] These data imply that understanding the characteristics of second primary cancers has
become more important in developing screening and management programs for cancer
survivors.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-
related deaths and known to have an extremely poor prognosis, with a 5-year survival rate of
<6%.[5] The median overall survival (OS) is 9 months for locally advanced pancreatic cancer
and 3–6 months for metastatic disease.[7] The only potentially curative therapy for pancreatic
cancer is surgical resection, and only 20% of pancreatic cancers are resectable at the time of
diagnosis. In addition to this dismal prognosis, to date, there is no effective screening tool for
high-risk patients and early screening for PDAC is not recommended for the general popula-
tion in terms of cost-effectiveness.[8]
Similar to patients with other second primary malignancies, there have been patients with
PDAC who developed another primary tumor in another organ or with a different histology.
To date, there are only a few studies about second primary PDAC (2nd PDAC). A study about
2nd PDAC with pooled analysis of international multicenter cancer registries reported that the
prevalence of 2nd PDAC among all patients with PDAC was about 6.3%.[9] There have been a
few studies which reported pancreatic cancer as a second primary malignancy, and observed
that the risk of second primary pancreatic cancer was increased after the development of vari-
ous malignancies.[10] Recently, a report about second primary pancreatic cancer in colorectal
cancer survivors showed that these patients have an increased risk of developing second pri-
mary pancreatic cancer.[11] However, although several studies have reported the increased
risk of 2nd PDAC in cancer survivors, data on the characteristics of 2nd PDAC are insuffi-
cient. Thus, we conducted a study on the characteristics of 2nd PDAC, with the premise that
our results might help in developing follow-up and screening strategies for cancer survivors,
and in elucidating the treatment for these patients with fatal PDAC.
Materials and methods
Study population and definitions
A retrospective patient cohort from Severance Hospital, Seoul, Korea, was examined. A total
of 1759 patients with PDAC, diagnosed as having ductal adenocarcinoma of the pancreas
according to histopathological findings between 2006 and 2014, were included in this study.
The age of the participants ranged from 44 to 91 years old.
The patients in the cohort were classified as having 2nd PDAC or first primary PDAC (1st
PDAC) according to the history of a prior cancer. Patients who met the following criteria
were considered as having 2nd PDAC: 1) the histological type of the prior cancer was not
adenocarcinoma; 2) if the histological type of the previous tumor was adenocarcinoma, the
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possibility of primary pancreatic cancer should be higher than that of metastasis or recur-
rence of the previous tumor based on specific immunohistochemical staining or a reliable
review by an experienced pathologist; and 3) PDAC was diagnosed at least 6 months after
the diagnosis of the prior cancer to exclude synchronous PDAC. If the patient had a history
of more than one prior cancer, the time of diagnosis of the first cancer was applied into the
criteria.
The following clinical characteristics of patients were collected: sex, age, smoking status,
alcohol consumption, history of diabetes and hypertension, CA19-9 level at diagnosis, primary
location of pancreatic cancer, resectability at diagnosis, initial treatment modality, origin of
another primary tumor, period between the time of diagnosis of another primary tumor and
that of the 2nd PDAC, and OS.
Statistical analysis
Data were analyzed by using the χ2, Fisher’s exact, and Student’s t-tests to compare variables
between the groups, and a p-value of <0.05 was considered statistically significant. The OS
and cumulative incidence rate of the 2nd PDAC after the diagnosis of other tumors were cal-
culated and analyzed by using Kaplan-Meier analysis with a log-rank test. Hazard ratios
(HRs), 95% confidence intervals (95% CIs), and p-values were calculated with a univariate
Cox proportional hazards model for OS, by using the variables that were statistically signifi-
cant. A multivariate Cox proportional hazards model was built to evaluate possible signifi-
cant factors, taking into account the possible influence of confounding clinical variables.
Only those variables that were significant in univariate analysis were entered into the multi-
variate analysis. Statistical analyses were carried out with Predictive Analytics Software statis-
tics version 23.
Ethical review
All procedures performed in studies involving human participants were in accordance with
the ethical standards of the institutional research committee and with the 1964 Helsinki decla-
ration and its later amendments or comparable ethical standards. As a retrospective analysis,
Yonsei University Health System, Severance Hospital, Institutional Review Board approval
was obtained and the need for informed consent was waived.
Results
Baseline characteristics
A total of 1759 patients with PDAC were included in the cohort. Forty-three patients were
classified as having synchronous 2nd PDAC and excluded from the analysis. There were 1606
patients (93.6%) with 1st PDAC and 110 patients (6.4%) with 2nd PDAC in the study popula-
tion (Table 1). Six patients (0.4%) had more than one prior cancer. In the comparison of base-
line characteristics between the 1st PDAC and 2nd PDAC groups (Table 1), patients with 2nd
PDAC presented significantly older age at diagnosis (66.5 vs. 62.2 years, p< 0.001), lower rate
of alcohol consumption (25.5 vs. 36.8%, p = 0.017), higher rate of resectability of PDAC (26.4
vs. 15.9%, p = 0.004), and higher rate of receiving surgery as the initial treatment (26.4 vs.
15.9%, p = 0.018) than patients with 1st PDAC. The origins of prior cancers accompanied with
2nd PDAC are summarized in Table 2. The most common origin of prior cancers was the
stomach (22 of 110, 20.0%), followed by the thyroid (21 of 110, 19.1%), breast (19 of 110,
17.3%), colon (12 of 110, 10.9%), and others.
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Survival analysis
The OS was slightly longer in patients with 2nd PDAC; however, the difference was not signifi-
cant (11.8 vs. 12.3 months, p = 0.068). Multivariate analysis without resectable status showed
that 2nd PDAC (HR 0.73, 95% CI 0.56–0.94, p = 0.016), age at diagnosis (HR 1.02, 95% CI
1.01–1.02, p < 0.001), and alcohol consumption (HR 1.28, 95% CI 1.13–1.47, p< 0.001) were
significantly related to OS (Table 3). When resectable status was included in multivariate anal-
ysis, age at diagnosis (HR 1.02, 95% CI 1.01–1.02, p< 0.001), alcohol consumption (HR 1.25,
95% CI 1.11–1.42, p = 0.001), and resectable status at diagnosis (HR 0.30, 95% CI 0.25–0.36,
p< 0.001) were significantly associated with OS. However, 2nd PDAC (HR 0.85, 95% CI
0.66–1.09, p = 0.198) was no longer significantly associated with OS after adjusting for resect-
able status. This analysis suggested that the association between 2nd PDAC and survival was
owing to the higher resectability rate.
Table 1. Baseline characteristics of subgroups.
Total 1st PDAC 2nd PDAC P-value
Patients 1716 (100%) 1606 (93.6%) 110 (6.4%)
Age, mean (SD) 62.5 (±10.3) 62.2 (±10.3) 66.5 (±9.6) <0.001
Sex 0.335
Women 705 (41.1%) 655 (40.8%) 50 (45.5%)
Men 1011 (63.9%) 951 (59.2%) 60 (54.5%)
Alcohol 0.017
Yes 619 (36.1%) 591 (36.8%) 28 (25.5%)
No 1097 (63.9%) 1015 (63.2%) 82 (74.5%)
Smoking 0.067
Yes 557 (32.5%) 530 (33.0%) 27 (24.5%)
No 1159 (67.5%) 1076 (67.0%) 83 (75.5%)
Diabetes 0.817
Yes 560 (32.6%) 523 (32.6%) 37 (33.6%)
No 1156 (67.4%) 1083 (67.4%) 73 (66.4%)
Hypertension 0.940
Yes 661 (38.5%) 619 (38.5%) 42 (38.2%)
No 1055 (61.5%) 987 (61.5%) 68 (61.8%)
Initial CA19-9 (U/mL) 3591.5 (±6336.9) 3620.8 (±6377.5) 3169.0(±5730.9) 0.474
Location of main mass 0.219
Head 774 45.1%) 727 (45.3%) 47 (42.7%)
Body 394 (23.0%) 361 (22.5%) 33 (30.0%)
Tail 315 (18.4%) 295 (18.4%) 20 (18.2%)
Overlap 233 (13.6%) 223 (13.9%) 10 (9.1%)
Resectability 0.004
Resectable 285 (16.6%) 256 (15.9%) 29 (26.4%)
Unresectable 1431 (83.45%) 1350 (84.1%) 81 (73.6%)
Initial treatment 0.018
Surgery 285 (16.6%) 256 (15.9%) 29 (26.4%)
Chemotherapy 1160 (67.6%) 1094 (68.1%) 66 (60.0%)
No treatment 271 (15.8%) 256 (15.9%) 15 (13.6%)
Median OS, months 11.8 (0.0–100.6) 11.8 (0.0–100.6) 12.3 (0.3–86.5) 0.068
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; OS, overall survival.
https://doi.org/10.1371/journal.pone.0179784.t001
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To exclude the confounding effect of the resectability of PDAC on OS, we divided the
whole cohort according to the initial treatment modality for PDAC: 1) patients who received
curative surgery and 2) patients who received chemotherapy. Then, the OS of patients with 1st
PDAC and those with 2nd PDAC was compared with Kaplan-Meier analysis according to
treatment modality (Fig 1). In the subgroup of patients who received curative surgery (Fig 1B),
the median OS was 28.5 months (95% CI, 23.0–34.1) in the 1st PDAC group compared with
33.1 months (95% CI, 9.0–27.2) in the 2nd PDAC group (n: 259 vs. 29, p = 0.860). In the sub-
group of patients who received chemotherapy (Fig 1C), the median OS was 10.7 months
Table 2. Origins of prior cancers accompanied with second primary PDAC.
Other cancer origins Patient number Interval since prior cancer, years (range)
Total 110 (100%) 8.4 (0.7–31.4)
Stomach 22 (20.0%) 11.2 (1.3–23.2)
Thyroid 21 (19.1%) 5.0 (1.2–30.5)
Breast 19 (17.3%) 9.5 (1.8–30.5)
Colon 12 (10.9%) 5.3 (0.7–26.8)
Prostate 5 (4.5%) 2.9 (0.8–10.0)
Rectum 5 (4.5%) 9.3 (3.0–14.2)
Head and neck 4 (3.6%) 9.0 (2.7–17.3)
Bile duct 3 (2.7%) 6.5 (5.8–11.6)
Cervix 3 (2.7%) 19.2 (17.3–31.4)
Bladder 3 (2.7%) 2.1 (1.2–13.1)
Lung 2 (1.8%) 10.6 (5.3–15.9)
Ovary 2 (1.8%) 9.8 (9.5–10.0)
Hematologic malignancy* 2 (1.8%) 4.3 (2.6–6.1)
Liver 1 (0.9%) 1.6 (1.6–1.6)
Kidney 1 (0.9%) 14.8 (14.8–14.8)
Esophagus 1 (0.9%) 4.5 (4.5–4.5)
AOV 1 (0.9%) 9.1 (9.1–9.1)
Endometrium 1 (0.9%) 12.8 (12.8–12.8)
Brain 1 (0.9%) 7.5 (7.5–7.5)
Other† 1 (0.9%) 10.7 (10.7–10.7)
*Hematologic malignancy: one multiple myeloma and one aplastic large-cell lymphoma.
†Other: a paratesticular tumor (soft tissue cancer).
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; AOV, ampulla of Vater.
https://doi.org/10.1371/journal.pone.0179784.t002
Table 3. Cox proportional analysis for the contribution of clinical factors to overall survival.
Univariate Multivariate Multivariate*
P-value HR (95% CI) P-value HR (95% CI) P-value
Second PDAC 0.093 0.73 (0.56–0.94) 0.016 0.85 (0.66–1.09) 0.198
Older age <0.001 1.02 (1.01–1.02) <0.001 1.02(1.01–1.02) <0.001
Male sex 0.056 1.04 (0.90–1.19) 0.627 1.03(0.90–1.19) 0.645
Alcohol use (vs. non-alcohol use) 0.001 1.28 (1.13–1.47) <0.001 1.25 (1.11–1.42) <0.001
Resectable disease (vs. unresectable) <0.001 Not included 0.30 (0.25–0.36) <0.001
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; HR, hazard ratio; CI, confidence interval.
* Multivariate analysis including resectable disease and multivariate analysis without resectable disease are separately presented.
https://doi.org/10.1371/journal.pone.0179784.t003
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(95% CI, 10.0–11.4) in 1st PDAC compared with 10.8 months (95% CI, 9.2–12.3) in 2nd
PDAC (n: 1094 vs. 66, p = 0.952). The effectiveness of either surgery or chemotherapy was sim-
ilar between the 2nd and 1st PDAC groups.
To compare differences according to the follow-up modality that might be different
depending on the location of the prior cancer, we divided patients with 2nd PDAC into those
with a prior cancer originating from the abdomen and those with prior cancer of non-abdomi-
nal origin (Table 4). The origin of abdominal prior cancers included the gastrointestinal tract
(stomach, colon, rectum), hepatobiliary tract (liver, bile duct), genitourinary tract (prostate,
bladder, kidney), gynecologic system (cervix, endometrium, and ovary), and other sites in the
abdominal and pelvic cavities. Other cancers originating from the thyroid, breast, head and
neck, lung, and brain were included in the non-abdominal prior cancer group. There were 63
patients (57.2%) with abdominal prior cancer and 47 patients (42.7%) with non-abdominal
prior cancer. In the comparison analysis, there were no significant differences in resectability
(27.0 vs. 25.5%, p = 0.864) or OS (11.3 vs. 14.5 months, p = 0.212) between groups.
In addition, we analyzed ratios of incidental findings on abdominal follow-up diagnostics
in comparison to symptomatic 2nd primary PDAC, which led to scan-diagnostics in the first
place. There were 47 patients who were diagnosed with 2nd PDAC on follow-up abdominal
CT/MRI scans and 63 patients who were diagnosed with 2nd PDAC by symptoms. Comparing
the two groups, the rate of resectable disease was significantly higher in the patients who were
diagnosed by follow-up abdominal CT/MRI scans than those diagnosed by symptoms presen-
tation (36.2% vs. 19.0%, p = 0.044).
Cumulative incidence rate of 2nd PDAC after diagnosis of another
primary tumor
The median interval between the diagnosis of the 2nd PDAC and the diagnosis of the prior
cancer was 8.4 years (range 0.7–31.4 years) in the 2nd PDAC group (Table 2). Among prior
cancers with a ratio of>10%, the median interval of stomach cancer was the longest at 11.2
years (range 1.3–23.2 years). Thyroid cancer presented the shortest interval to 2nd PDAC at
5.0 years (range 1.2–30.5 years). Fig 2 shows the cumulative incidence rate of 2nd PDAC after
the diagnosis of prior cancer in the 2nd PDAC group. The trend of the first 5 years was 7 cases
per year (35 cases every 5 years). Thereafter, every 5 years, the value decreased continuously to
Fig 1. Kaplan-Meier analysis of overall survival (OS) according to subgroup. (A) First primary
pancreatic ductal adenocarcinoma (1st PDAC) vs. second primary PDAC (2nd PDAC) in the whole cohort (n:
1606 vs. 110): median OS 11.8 vs. 12.3 months, p = 0.068 by log-rank test. (B) 1st PDAC vs. 2nd PDAC in
patients who received curative surgery as initial treatment (n: 256 vs. 29): median OS 28.5 vs. 33.1 months,
p = 0.860 by log-rank test. (C) 1st PDAC vs. 2nd PDAC in patients who received chemotherapy as initial
treatment (n: 1094 vs. 66): median OS 10.7 vs. 10.8 months, p = 0.952 by log-rank test.
https://doi.org/10.1371/journal.pone.0179784.g001
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6.4, 3.8, 2.8, 1.2, and 0.6 cases per year until 30 years. The cumulative incidence rate was 60.9%
at 10 years, 90.9% at 20 years, and 99.1% at 30 years after the diagnosis of prior cancer.
Discussion
Previously, there were a few studies about 2nd PDAC with a population-based analysis. These
studies reported that cancer survivors have an increased risk of developing 2nd PDAC.[10, 12,
13] Although there have been reports about the increased risk of 2nd PDAC in cancer survi-
vors, there have been few studies about how the 2nd PDAC was different from the 1st PDAC.
Hackert et al reported features of patients with PDAC and history of extrapancreatic malig-
nancy compared to patients with PDAC as only tumor, however, the results of the study were
limited to patients who underwent surgery for PDAC.[14] Considering the fatality of pancre-
atic cancer, an increased risk of pancreatic cancer in cancer survivors necessitates more atten-
tion on 2nd PDAC. In that context, we aimed to analyze the characteristics of 2nd PDAC in
this study.
In this study, there were 110 patients with 2nd PDAC among a total of 1716 patients with
PDAC. The proportion of patients with 2nd PDAC was about 6.4%, and this percentage was
compatible with that reported in a previous study.[9] The considerable proportion of patients
with 2nd PDAC in the entire pancreatic cohort again suggests that more attention should be
paid to this specific subset of patients with pancreatic cancer.
Table 4. Comparison of subgroups according to the location of the prior cancer in second PDAC.
Abdomen Non-abdomen P-value
Patients 63 (57.2%) 47 (42.7%)
Age, mean (SD) 67.8 (±9.7) 64.7 (±9.4) 0.087
Sex <0.001
Women 16 (25.4%) 34 (72.3%)
Men 47 (74.6%) 13 (27.7%)
Interval from prior cancer 8.9 (0.7–31.4) 8.4 (1.2–30.5) 0.766
Alcohol 18 (28.6%) 10 (21.3%) 0.385
Smoking 20 (31.7%) 7 (14.9%) 0.042
Diabetes 23 (36.5%) 14 (29.8%) 0.461
Hypertension 40 (63.5%) 28 (59.6%) 0.676
Initial CA19-9 (U/mL) 2957.0 (±5596.2) 3454.8 (±5957.8) 0.657
Location of main mass 0.553
Head 24 (38.1%) 23 (48.9%)
Body 19 (30.2%) 14 (29.8%)
Tail 14 (22.2%) 6 (12.8%)
Overlap 6 (9.5%) 4 (8.5%)
Resectability 0.864
Resectable 17 (27.0%) 12 (25.5%)
Unresectable 46 (73.0%) 35 (74.5%)
Initial treatment 0.352
Surgery 17 (27.0%) 12 (24.6%)
Chemotherapy 35 (55.6%) 31 (66.0%)
No treatment 11 (17.5%) 4 (8.5%)
Median OS, months 11.3 (0.3–86.5) 14.5 (0.4–68.9) 0.212
Abbreviations: SD, standard deviation; OS, overall survival.
https://doi.org/10.1371/journal.pone.0179784.t004
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In our results, the patient age at diagnosis of 2nd PDAC was older than that of 1st PDAC
(66.5 vs. 62.2 years, p< 0.001). Similarly, in a previous report, there were more patients >75
years old (46% vs. 32%) and fewer patients <65 years old (22% vs. 37%) in the 2nd PDAC
group than in the 1st PDAC group.[9] This result concurs with another study which reported
that patients with PDAC and history of extrapancreatic neoplasm presented at older age
than patients with PDAC as only tumor in patients who underwent surgery (68 vs. 64 years,
p< 0.0001).[14] There seemed to be a tendency that patients with second primary cancer are
older than patients with first primary cancer at the time of diagnosis. A previous study about
second primary non-small cell lung cancer (NSCLC) reported that the group of patients with
NSCLC with a history of another tumor presented older age at diagnosis (71 vs. 66 years) than
did patients with NSCLC as the only tumor, similar to our result.[15] The age at diagnosis
might be different because old age is one of the risk factors of cancer and patients with second
primary cancer had lived long enough to survive the prior cancer.
The rate of alcohol consumption (25.5 vs. 36.8%, p = 0.017) was lower in the 2nd PDAC
group in our results. This might be because of the tendency of patients to stop drinking alcohol
upon the diagnosis of cancer. Like our study, a previous study reported that the onset of cancer
was significantly associated with cessation of alcohol consumption, based on cohort data from
9001 Korean patients.[16]
In the multivariate analysis after adjusting for confounding factors such as older age at diag-
nosis of 2nd PDAC, 2nd PDAC was significantly associated with a longer OS compared with
1st PDAC (HR 0.73, p = 0.016). However, after adjusting for resectability at diagnosis, 2nd
Fig 2. Cumulative curve of diagnosis of second pancreatic ductal adenocarcinoma (PDAC).
Cumulative incidence rate of second primary PDAC (2nd PDAC) after the diagnosis of prior cancer in the 2nd
PDAC group. The median interval between the diagnosis of the 2nd PDAC and the diagnosis of the prior
cancer was 8.4 years. The cumulative rates (cumulative cases for every 5 years after the diagnosis of prior
cancer) are presented as a table.
https://doi.org/10.1371/journal.pone.0179784.g002
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PDAC was no longer significantly associated with OS. In fact, the rate of resectability of 2nd
PDAC was significantly higher than that of 1st PDAC (26.4 vs. 15.9%, p = 0.004). Furthermore,
more patients with 2nd PDAC could receive curative surgery, which could potentially increase
their OS. When the whole cohort was divided into subgroups according to initial treatment
modality (curative surgery or chemotherapy), there was no difference in OS between 2nd
PDAC and 1st PDAC in both subgroups. These results suggest that the OS of the 2nd PDAC
group seemed to be longer because there were more resectable cases at the time of diagnosis.
Concerning the treatment, it can be presumed that that the nature of 2nd PDAC and 1st
PDAC was not much different. When surgery of curative aim was possible, the OS was
increased even in patients with 2nd PDAC. This result suggests the need to develop screening
programs for detecting resectable pancreatic cancer in cancer survivors.
To identify the effect of follow-up methods that might be different depending on the ana-
tomical distribution of the prior cancer, we compared the subgroups divided according to
the location of prior cancer in the 2nd PDAC group. When comparing cancers of abdominal
origin, which were closer to the pancreas, and those of non-abdominal origin, there were
no significant differences between subgroups in terms of resectability (p = 0.864) or OS
(p = 0.212). It seems that the origin of prior cancer was not related to the tendency of early
detection of 2nd PDAC. Interestingly, the rate of resectable disease was significantly higher
in the patients who were diagnosed by follow-up abdominal CT/MRI scans than those diag-
nosed by presentation of symptomatic 2nd PDAC, which led to scan-diagnostics in the first
place. It seemed that there was a correlation between early detection and follow-up methods,
which suggested the necessity of developing screening programs for 2nd PDAC. However,
there were only 110 patients with 2nd PDAC in this study, and follow-up intervals and
methods were heterogeneous. A larger study with subgroup analysis according to the cell
types or common etiologies shared by prior cancers should be conducted in the future.
Most importantly, an optimal follow-up program for 2nd PDAC should be developed and
evaluated.
The cumulative curve of diagnosis of 2nd PDAC is presented in Fig 2. According to our
analysis, the median interval from prior cancer to 2nd PDAC was 8.4 years, and the cumulative
rate of diagnosis of 2nd PDAC continuously increased for 10 years with inclination similar to
the first 5 years (6.4 and 5.8 cases per year). The graph was steadily increasing for 20 years with
a 90.9% cumulative rate and then reached a plateau. This result implies that cancer screening
in cancer survivors and regular follow-up need to continue up to 20 years after the diagnosis of
prior cancer, which is longer than the usual current follow-up period for most cancers. In our
study, the most common prior cancer of 2nd primary PDAC was stomach cancer (20.0%), fol-
lowed by thyroid cancer (19.1%), breast cancer (17.3%), colon cancer (10.9%), and others.
This result was compatible with the prevalence and OS of these cancers in Korea. According to
Cancer Statistics 2013 in Korea,[17] the most common origin of cancer was the stomach
(17.8%) and colon (14.6%) in men. In women, thyroid cancer (30.5%) was the most common
and breast cancer (15.4%) was the second common malignancy. In our study, there were only
a few patients with lung cancer or liver cancer as the prior cancer, although these cancers are
highly prevalent in Korea. This result was presumed to be because of the poor survival of
patients with liver and lung cancers.
This study has several limitations. The number of patients with 2nd PDAC was small com-
pared with those with 1st PDAC, although the proportion of 2nd PDAC in the total cases of
PDAC was compatible with a previous study. In addition, we did not consider the possibility
of multicancer syndromes accompanied with genetic disorders and the presence of premalig-
nant lesions of PDAC such as intraductal papillary mucinous tumor. To overcome such limita-
tions, larger prospective studies are needed in the future.
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Conclusions
Second primary pancreatic cancer had a higher rate of resectability, and there was no differ-
ence in the effectiveness of curative surgery and chemotherapy between 2nd and 1st PDAC.
Therefore, when curative surgery for 2nd PDAC is possible, it should be conducted similarly
to curative surgery for 1st PDAC. Considering the increased risk of 2nd PDAC in cancer survi-
vors and the fact that surgery is the only curative treatment for this fatal cancer, more efforts
are needed to develop screening programs for second primary pancreatic cancer in cancer
survivors.
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